1	Debe	deber	VMIP3S0	-	-	0-4	760(0)_ANS_clinical_caseMIR	SENT1	-	-
2	administrar	administrar	VMN0000	C1621583	calificador	5-16	760(0)_ANS_clinical_caseMIR	SENT1	-	-
3	se	se	PP3CN000	-	-	16-18	760(0)_ANS_clinical_caseMIR	SENT1	-	-
4	rituximab	rituximab	NC00SC0	C0393022	producto#sustancia	19-28	760(0)_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
5	,	,	Fc	-	-	28-29	760(0)_ANS_clinical_caseMIR	SENT1	-	-
6	puesto	poner	VMP00SM	-	-	30-36	760(0)_ANS_clinical_caseMIR	SENT1	-	-
7	que	que	CS	-	-	37-40	760(0)_ANS_clinical_caseMIR	SENT1	-	-
8	los	el	DA0MP0	-	-	41-44	760(0)_ANS_clinical_caseMIR	SENT1	-	-
9	glucocorticoides	glucocorticoide	NCMP000	C0017710	producto#sustancia	45-61	760(0)_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
10	han	haber	VAIP3P0	-	-	62-65	760(0)_ANS_clinical_caseMIR	SENT1	-	-
11	quedado	quedar	VMP00SM	-	-	66-73	760(0)_ANS_clinical_caseMIR	SENT1	-	-
12	relegados	relegar	VMP00PM	-	-	74-83	760(0)_ANS_clinical_caseMIR	SENT1	-	-
13	a	a	SPS00	-	-	84-85	760(0)_ANS_clinical_caseMIR	SENT1	-	-
14	un	un		C0205447_1	calificador_1	86-88	760(0)_ANS_clinical_caseMIR	SENT1	-	-
15	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	89-100	760(0)_ANS_clinical_caseMIR	SENT1	-	-
16	de	de	SPS00	C0332285	atributo	101-103	760(0)_ANS_clinical_caseMIR	SENT1	-	-
17	segunda	2	AO0FS0	-	-	104-111	760(0)_ANS_clinical_caseMIR	SENT1	-	-
18	línea	línea	NCFS000	C0205132	calificador	112-117	760(0)_ANS_clinical_caseMIR	SENT1	-	-
19	debido	deber	VMP00SM	C0678226_1	atributo_1	118-124	760(0)_ANS_clinical_caseMIR	SENT1	-	-
20	a	a	SPS00	C0678226_2	atributo_2	125-126	760(0)_ANS_clinical_caseMIR	SENT1	-	-
21	sus	su	DP3CP0	-	-	127-130	760(0)_ANS_clinical_caseMIR	SENT1	-	-
22	efectos	efecto	NCMP000	C1704419#C1280500#C1280519	calificador	131-138	760(0)_ANS_clinical_caseMIR	SENT1	-	-
23	secundarios	secundario	AQ0MP0	C0175668	calificador	139-150	760(0)_ANS_clinical_caseMIR	SENT1	-	-
24	.	.	Fp	-	-	151-152	760(0)_ANS_clinical_caseMIR	SENT1	-	-

